SELECTIVE ADDRESSED THERAPY OF PROSTATE CANCER TARGETED TO THE VASCULAR FOLLICLE-STIMULATING HORMONE RECEPTOR

  • Radu, Aurelian N. (PI)

Project Details

Description

The project is based on the presence in the human prostate tumors of a newly discovered protein, FSHR. In normal male tissues, the protein is present only in a subset of cells in the testis. The protein is exposed on the surface of the tumor blood vessels, which makes it directly accessible to therapeutic agents injected in the blood. We will take advantage of this newly discovered tumor marker by synthesizing and testing agents that carry therapeutic agents to this target inside the tumors. The agent will contain a targeting component and an effector component. After intravenous delivery, the agents will bind to FSHR that is exposed on the tumor blood vessels, will be internalized in the cells that form the walls of the blood vessels, and will deliver toxins to these cells. As a consequence, the agents will destroy the tumor blood vessels and will deprive the tumors of oxygen and nutrients. The ability of the agents to bind to the target and to induce cell death will be tested in cell cultures. Subsequently, the agents will be tested in mice that carry tumor generated by prostate human tumor cells. It will be verified that the agents inhibit tumor growth, while having minimal effects on the normal tissues.

StatusFinished
Effective start/end date1/02/1431/01/15

Funding

  • Congressionally Directed Medical Research Programs: $127,125.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.